Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In ObesitySeeking Alpha • 02/09/26
14 Ideal 'Safer' Dividend Buys From 29 Of 69 February Graham Value All-Stars (GVAS)Seeking Alpha • 02/06/26
FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical NeedBusiness Wire • 02/06/26
Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of AmericansBusiness Wire • 02/06/26
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026The Motley Fool • 02/04/26
Will the Market Crash in 2026? Here's What History Says and What to Do About ItThe Motley Fool • 02/04/26
Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug DataZacks Investment Research • 02/03/26
Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As EverSeeking Alpha • 02/03/26
Pfizer (PFE) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 02/03/26